- GlobeNewswire•15 days agoKamada Announces Extension of GLASSIA® Supply and Distribution Agreement with Shire with Minimum $237 Million of Revenue for the Years 2017 to 2020
NESS ZIONA, Israel, Oct. 06, 2016-- Kamada Ltd., a plasma-derived protein therapeutics company focused on orphan indications, announced today the extension of the strategic partnership with Shire plc for ...
- Accesswire•last month
Lead Product Glassia is Approved in Large and Growing AAT Deficiency Market; Report Available here: http://www.lifescicapital.com/equity-research/kamada/ NEW YORK, NY / ACCESSWIRE / September 12, 2016 ...
Kamada Ltd. (KMDA)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
|Bid||5.61 x 200|
|Ask||5.69 x 200|
|Day's Range||5.55 - 5.66|
|52wk Range||3.26 - 5.86|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||-26.95|
|Avg Vol (3m)||24,381|
|Dividend & Yield||N/A (N/A)|